BRIEF published on 11/04/2024 at 11:51, 9 hours 57 minutes ago Acticor Biotech : Publication des résultats financiers semestriels 2024 Résultats Semestriels Biotechnologie Finance Redressement Judiciaire Glenzocimab
BRIEF published on 11/04/2024 at 11:51, 9 hours 57 minutes ago Acticor Biotech: Publication of 2024 half-year financial results Biotechnology Finance Half-year Results Glenzocimab Judicial Recovery
PRESS RELEASE published on 11/04/2024 at 11:46, 10 hours 2 minutes ago Informations privilégiées / Communiqué sur comptes, résultats Acticor Biotech publie ses résultats financiers semestriels 2024 et annonce le repositionnement du glenzocimab dans le traitement de l’infarctus du myocarde avec élévation du segment ST (STEMI) Résultats Financiers ACTICOR BIOTECH Glenzocimab Repositionnement Infarctus Du Myocarde
PRESS RELEASE published on 11/04/2024 at 11:46, 10 hours 2 minutes ago Inside Information / News release on accounts, results Acticor Biotech publishes its half-year financial results for 2024, highlighting repositioning of glenzocimab in STEMI treatment, receivership proceedings extension, and shareholder approvals Repositioning Shareholder Approvals ACTICOR BIOTECH Glenzocimab Half-year Financial Results
BRIEF published on 10/11/2024 at 17:50, 24 days 3 hours ago Acticor Biotech Advances Glenzocimab in Myocardial Infarction Treatment Clinical Trials Myocardial Infarction ACTICOR BIOTECH Glenzocimab Cardiovascular Treatment
BRIEF published on 10/11/2024 at 17:50, 24 days 3 hours ago Acticor Biotech fait progresser le Glenzocimab dans le traitement de l'infarctus du myocarde Essais Cliniques ACTICOR BIOTECH Glenzocimab Infarctus Du Myocarde Traitement Cardiovasculaire
PRESS RELEASE published on 10/11/2024 at 17:45, 24 days 4 hours ago Inside Information / Other news releases Acticor Biotech repositions glenzocimab in the treatment of myocardial infarction, evaluating efficacy and safety in phase 2 studies LIBERATE and GLORIA. Clinical trials aim to reduce infarct size and prevent complications Clinical Trials Phase 2b Myocardial Infarction ACTICOR BIOTECH Glenzocimab
PRESS RELEASE published on 10/11/2024 at 17:45, 24 days 4 hours ago Informations privilégiées / Autres communiqués Repositionnement de glenzocimab dans le traitement de l'infarctus du myocarde par Acticor Biotech. Nouvelle étude de phase 2b LIBERATE et préparation de l'étude GLORIA Traitement Étude Clinique ACTICOR BIOTECH Glenzocimab Infarctus Du Myocarde
BRIEF published on 07/09/2024 at 20:50, 3 months 26 days ago Acticor Biotech Reports 2023 Financial Results Financial Report Annual Results Capital Raising ACTICOR BIOTECH Glenzocimab
BRIEF published on 07/09/2024 at 20:50, 3 months 26 days ago Acticor Biotech publie ses résultats financiers pour 2023 Résultats Annuels Rapport Financier ACTICOR BIOTECH Glenzocimab Levée De Capitaux
Published on 11/04/2024 at 21:30, 18 minutes ago Forward Water Technologies Corp. Announces Shares for Interest Debt Settlement
Published on 11/04/2024 at 20:45, 1 hour 3 minutes ago Koilink Technologies Inc. Appoints Transfer Online Inc. as New Transfer Agent, Enhancing Shareholder Services Amid Progress Toward Public Listing
Published on 11/04/2024 at 19:00, 2 hours 48 minutes ago Arctic IT Government Solutions Selected as an Information Technology Support Services Contractor for the U.S. Department of the Interior, Bureau of Indian Affairs
Published on 11/04/2024 at 18:15, 3 hours 33 minutes ago Al Salam Bank Launches ASB Capital: A New Asset Management Firm in the DIFC with AUMs of USD 4.5 Billion
Published on 11/04/2024 at 17:30, 4 hours 18 minutes ago Park Lawn Further Expands in Texas Through Acquisition of Callaway Jones
Published on 11/04/2024 at 21:15, 32 minutes ago EQS-Adhoc: LEG Immobilien SE: Acquisition of Brack Capital Properties N.V. through the conclusion of a share purchase agreement and a tender commitment in the event of a public offer
Published on 11/04/2024 at 19:00, 2 hours 47 minutes ago EQS-Adhoc: Salzgitter Aktiengesellschaft: Potential voluntary public takeover bid to the shareholders of Salzgitter AG
Published on 11/04/2024 at 19:00, 2 hours 48 minutes ago PATRIMOINE ET COMMERCE: Déclaration des transactions sur actions propres (Hors contrat de liquidité) réalisées du 28 OCTOBRE 2024 au 01 NOVEMBRE 2024
Published on 11/04/2024 at 19:00, 2 hours 48 minutes ago PATRIMOINE ET COMMERCE: INFORMATIONS RELATIVES AU NOMBRE TOTAL DE DROITS DE VOTE ET AU NOMBRE D’ACTIONS COMPOSANT LE CAPITAL SOCIAL AU TITRE DE L’ARTICLE 223-16 DU REGLEMENT GENERAL DE L'AMF
Published on 11/04/2024 at 18:13, 3 hours 35 minutes ago Thales : lancement de l’opération 2024 d’actionnariat salarié
Published on 11/04/2024 at 18:13, 3 hours 35 minutes ago Thales: Launch of the 2024 Employee Share Ownership Plan
Published on 11/04/2024 at 18:11, 3 hours 36 minutes ago Monthly disclosure of the total number of shares and voting rights - 31/10/2024
Published on 11/04/2024 at 18:11, 3 hours 36 minutes ago Déclaration mensuelle des actions et droits de vote – 31/10/2024
Published on 11/04/2024 at 17:45, 4 hours 3 minutes ago Disclosure of trading in own shares from October 29th, 2024, to November 1st, 2024. Detailed information per transaction.
